UK markets closed

Ultragenyx Pharmaceutical Inc. (RARE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
40.75+0.17 (+0.42%)
As of 12:51PM EDT. Market open.
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
442,586
434,249
363,329
351,406
271,030
-
Cost of revenue
50,485
45,209
28,320
16,008
6,129
-
Gross profit
392,101
389,040
335,009
335,398
264,901
-
Operating expenses
Research development
661,238
648,449
705,789
497,153
412,084
-
Selling general and administrative
311,313
309,799
278,139
219,982
182,933
-
Total operating expenses
972,551
958,248
983,928
717,135
595,017
-
Operating income or loss
-580,450
-569,208
-648,919
-381,737
-330,116
-
Interest expense
66,215
66,004
43,015
29,422
33,291
-
Total other income/expenses net
2,227
60
-20,865
-43,750
171,010
-
Income before tax
-615,216
-608,464
-701,725
-452,981
-185,359
-
Income tax expense
-1,865
-1,825
5,696
1,044
1,207
-
Income from continuing operations
-613,351
-606,639
-707,421
-454,025
-186,566
-
Net income
-613,351
-606,639
-707,421
-454,025
-186,566
-
Net income available to common shareholders
-613,351
-606,639
-707,421
-454,025
-186,566
-
Basic EPS
-8.97
-
-10.12
-6.70
-3.07
-7.12
Diluted EPS
-8.97
-
-10.12
-6.70
-3.07
-7.12
Basic average shares
70,780
-
69,914
67,796
60,846
56,577
Diluted average shares
70,780
-
69,914
67,796
60,846
56,577